Skip to main content

09-02-2017 | Image

Figure 5. Dysregulated signaling pathways involved in lymphomas.

Several aberrantly activated regulatory pathways are involved in lymphomagenesis. Among them, the NF-κB and BCR pathways are most commonly aberrantly activated. Some key components of these pathways and relevant upstream and downstream molecules are emerging as biomarkers to yield prognostic and therapeutic information. BAFF-R, B-cell activating factor receptor; BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; CARD11, caspase recruitment domain family, member 11; IKK, IκB kinase; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; NEMO, NF-κB essential modifier; NIK, NF-κB-inducing kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3 kinase; TCR, T-cell receptor; TLRs, Toll-like receptors; TNFR, tumor necrosis factor receptor.